London, UK, 23 OCTOBER 2024
30 Technology is excited to announce that on October 16, 2024, the first patient was enrolled into the NOPA study. NOPA is a Phase I/II clinical trial to assess the safety, tolerability, and efficacy of RESP303 over 28 days in NCFB patients with high-titre Pseudomonas Aeruginosa colonisation. RESP303 is a new Nitric Oxide generating inhaled antimicrobial which is the first of 30 Technology’s next generation inhaled assets.
Dr Syed Jafri, Chief Medical Officer, 30 Technology stated:
“We are delighted with the progress achieved in the NOPA trial, and eagerly anticipate the upcoming results. This accomplishment would not have been possible without the expert guidance from our Scientific Advisory Board and the invaluable contributions made by our clinical partners PPD, ARENSIA and Pharmaxi”.